ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

122 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Eligible patients with severe cardiogenic shock will be randomized to one of the two arms: immediate ECMO therapy or early conservative therapy. In the invasive group, veno-arterial ECMO will be implanted according to the local practice with flow settings to ensure sufficient tissue perfusion. With the exception of ECMO implantation in the invasive group, all other diagnostic and therapeutic procedures will be done according to the current standard of care at the tertiary cardiovascular center, including other cardiovascular interventions (i.e. percutaneous coronary intervention or cardiac surgery). Implantation of other mechanical support devices including ECMO in the primary conservative group is allowed in the case of shock progression with rise of serum lactate by 3 mmol/L in comparison with the lowest value during the past 24 hours. Follow-up include visits at 30 days, 6 moths and 12 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Left Ventricular unLoading by Impella vs Intra-aortic Balloon Pump

NCT06645990

Cardiogenic Shock

RECRUITING

Extracorporeal Life Support in Cardiogenic Shock

NCT03637205

Acute Myocardial Infarction Cardiogenic Shock

COMPLETED NA

LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients

NCT04728932

Cardiogenic Shock Extracorporeal Membrane Oxygenation Complication

COMPLETED PHASE3

A Study on the Effects of Left Ventricular Unloading in the Setting of VA ECMO Support

NCT05913622

Cardiogenic Shock

RECRUITING NA

Blood Management During ECMO for Cardiac Support

NCT03714048

Death, Sudden, Cardiac HEART ARREST Shock, Cardiogenic +6 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiogenic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Invasive

Immediate veno-arterial extracorporeal membrane oxygenation (ECMO)

Group Type ACTIVE_COMPARATOR

Veno-arterial extracorporeal membrane oxygenation (ECMO)

Intervention Type DEVICE

Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.

Conservative

Early conservative therapy according to standard practice

Group Type ACTIVE_COMPARATOR

Early conservative therapy according to standard practice

Intervention Type OTHER

Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Veno-arterial extracorporeal membrane oxygenation (ECMO)

Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.

Intervention Type DEVICE

Early conservative therapy according to standard practice

Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients must fulfil criteria for rapidly deteriorating (A) or severe (B) cardiogenic shock:

A. Rapidly deteriorating cardiogenic shock is defined as progressive hemodynamic instability necessitating repeated bolus administration of vasopressors to maintain mean arterial pressure \> 50 mmHg + impaired left ventricle systolic function (Left ventricle ejection fraction (LVEF) \< 35% or LVEF 35-55% in case of severe mitral regurgitation or aortic stenosis) or

B. In severe cardiogenic shock all following criteria should be met:

1. Hemodynamic:

Cardiac Index (CI) \< 2.2 L/min/m2 + norepinephrine dose \> 0.1 μg/kg/min + dobutamin dose \> 5 μg/kg/min or Systolic blood pressure \< 100 mmHg + norepinephrine dose \> 0.2 μg/kg/min + dobutamin dose \> 5 μg/kg/min + (LVEF \< 35% or LVEF 35-55% + severe mitral regurgitation or aortic stenosis)
2. Metabolic:

Lactate - two consecutive values ≥ 3 mmol/L (with at least 30 min between samples), with non-decreasing trend on steady doses of inotropes and/or vasopressors or SvO2 - two consecutive values \< 50% (with at least 30 min between measurements), with non-increasing trend on steady doses of inotropes and/or vasopressors
3. Hypovolemia must be excluded:

Central venous pressure \> 7 mmHg or pulmonary capillary wedge pressure \> 12 mmHg

Exclusion Criteria

1. Age \< 18 years
2. Life expectancy lower than 1 year
3. High suspicion of pulmonary emboli or cardiac tamponade as a cause of shock
4. Significant bradycardia or tachycardia which might be responsible for hemodynamic instability and not treated by pacing or cardioversion
5. Cardiac arrest survivors remaining comatose
6. Hypertrophic obstructive cardiomyopathy
7. Peripheral artery disease disabling insertion of outflow cannula to femoral artery
8. Moderate to severe aortic regurgitation
9. Aortic dissection
10. Uncontrolled bleeding or TIMI major bleeding within last 6 months
11. Known encephalopathy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No